Stockscreener 앱 받기
2.715
1.09%
-0.03
시간 외 거래:
2.65
-0.065
-2.39%
전일 마감가:
$2.745
열려 있는:
$2.79
하루 거래량:
763.35K
Relative Volume:
1.27
시가총액:
$162.58M
수익:
-
순이익/손실:
$-40.33M
주가수익비율:
-1.5168
EPS:
-1.79
순현금흐름:
$-39.53M
1주 성능:
-19.67%
1개월 성능:
-20.61%
6개월 성능:
-42.23%
1년 성능:
+5.23%
1일 변동 폭
$2.67
$2.815
1주일 범위
$2.41
$3.51
52주 변동 폭
$2.375
$5.54
Eledon Pharmaceuticals Inc Stock (ELDN) Company Profile
명칭
Eledon Pharmaceuticals Inc
전화
949-238-8090
주소
19800 MACARTHUR BLVD., IRVINE
ELDN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ELDN
Eledon Pharmaceuticals Inc
|
2.715 | 205.99M | 0 | -40.33M | -39.53M | -1.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Eledon Pharmaceuticals Inc Stock (ELDN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-18 | 재개 | H.C. Wainwright | Buy |
| 2025-01-28 | 개시 | Guggenheim | Buy |
| 2022-05-13 | 재개 | Cantor Fitzgerald | Overweight |
| 2021-03-23 | 개시 | Cantor Fitzgerald | Overweight |
Eledon Pharmaceuticals Inc 주식(ELDN)의 최신 뉴스
Can trapped investors hope for a rebound in Eledon Pharmaceuticals Inc.Stock Entry Points Based on Technicals - Newser
Can Eledon Pharmaceuticals Inc. rally from current levelsRisk-Managed Trade Alerts for Consistency - Newser
Statistical indicators supporting Eledon Pharmaceuticals Inc.’s strengthRisk Shielded Trade Watch with Analysis - Newser
Can Eledon Pharmaceuticals Inc. hit a new high this monthMulti-Year Signal Summary and Entry Timing - Newser
Using Bollinger Bands to evaluate Eledon Pharmaceuticals Inc.Bear Market Safe Zone Technical Analysis - Newser
Has Eledon Pharmaceuticals Inc. Stock Ever Crashed Historical Volatility ReviewFree Trade Timing Strategy With Technical Data - Newser
Is Eledon Pharmaceuticals Inc. stock a good hedge against inflationTrade Plan With Low Risk High Return - Newser
Volatility clustering patterns for Eledon Pharmaceuticals Inc.Free High Return Stock Focus With Safety - Newser
Should you hold or exit Eledon Pharmaceuticals Inc. nowFree Access to Real-Time Trade Insights - Newser
Using portfolio simulators with Eledon Pharmaceuticals Inc. includedEarly Entry Ideas with Momentum Potential - Newser
Order flow analysis tools used on Eledon Pharmaceuticals Inc.Watchlist Generator With Real-Time Entry - Newser
Eledon Pharmaceuticals Inc. Company Revenue and Profit Trends: A Deep DiveWeekly Chart-Based Forecast for Traders - Newser
Why Eledon Pharmaceuticals Inc. is moving todayFree Smart Trend Trading with Weekly Signals - Newser
Eledon Pharmaceuticals Inc. stock outlook for YEARBuy and Hold Position Summary Review - Newser
What makes Eledon Pharmaceuticals Inc. stock price move sharplyWatchlist Generator for Smart Money Signals - Newser
Ipsen is no longer advancing Sutro’s ADC; Layoffs at Tune Therapeutics - Endpoints News
Custom watchlist performance reports with Eledon Pharmaceuticals Inc.Free Reliable Alerts for Daily Stock Movers - Newser
Eledon Pharmaceuticals shares rise 2.37% after-hours following updated Phase Ib data conference call. - AInvest
Mixed market reaction to Eledon Phase Ib trial for tegoprubart - The Pharma Letter
Eledon Plunges 17.15% on Clinical Trial Data, Oracle Rumors - AInvest
Promising Phase 1b Results of Tegoprubart Support Buy Rating for Eledon Pharmaceuticals - TipRanks
Eledon Pharmaceuticals shares fall 9.88% premarket despite positive Phase 1b trial data for tegoprubart. - AInvest
Real time alert setup for Eledon Pharmaceuticals Inc. performancePredictable Income Summary for Long-Term Trades - Newser
Eledon Pharmaceuticals Reports Promising Phase 1b Trial Results - TipRanks
Eledon Presents Updated Data from Ongoing Phase 1b Trial - GlobeNewswire
New Kidney Transplant Drug Outperforms Standard Treatment: 68 vs 53 eGFR Score in Phase 1b Trial - Stock Titan
Global Renal Transplant Therapeutics Market is Expected to Cross ~USD 18 Billion by 2032 | DelveInsight - GlobeNewswire Inc.
How Eledon Pharmaceuticals Inc. stock performs during market volatilityDaily Profit Watch With Forecast Confidence - Newser
Does Eledon Pharmaceuticals Inc. qualify in momentum factor screeningFree Growth Based Investment Plan Guidance - Newser
Combining price and volume data for Eledon Pharmaceuticals Inc.Chart Risk Profile for Capital Preservation - Newser
What institutional investors are buying Eledon Pharmaceuticals Inc. stockTriple-digit return opportunities - Jammu Links News
Eledon Pharmaceuticals Inc. Stock Analysis and ForecastFree Consultation - Jammu Links News
Does Eledon Pharmaceuticals Inc. stock perform well during market downturnsBuild a portfolio with strong long-term growth - Jammu Links News
What is the risk reward ratio of investing in Eledon Pharmaceuticals Inc. stockBuild wealth steadily with smart stock selection - Jammu Links News
How strong is Eledon Pharmaceuticals Inc. company’s balance sheetNavigate market volatility with smart strategies - Jammu Links News
Eledon Pharmaceuticals Inc (ELDN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):